{"id":48783,"date":"2025-11-22T22:20:20","date_gmt":"2025-11-22T14:20:20","guid":{"rendered":"https:\/\/flcube.com\/?p=48783"},"modified":"2025-11-22T22:20:21","modified_gmt":"2025-11-22T14:20:21","slug":"pien-tze-huangs-pzh2108-cancer-pain-drug-enrolls-first-phase-iia-patient","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48783","title":{"rendered":"Pien Tze Huang&#8217;s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient"},"content":{"rendered":"\n<p><strong>Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600436:SHA\">SHA: 600436<\/a>) announced the enrollment of the first patient in a <strong>Phase\u202fIIa<\/strong> clinical trial for <strong>PZH2108 tablets<\/strong>, a <strong>Class\u202f1 innovative chemical drug<\/strong> intended for the treatment of <strong>cancer pain<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-milestone\">Clinical Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>PZH2108 tablets<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Zhangzhou Pien Tze Huang Pharmaceutical (SHA: 600436)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase\u202fIIa<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cancer pain<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Multi\u2011center, randomized, double\u2011blind, placebo\u2011controlled<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Treatment\u2011emergent adverse events (TEAEs) and abnormal safety assessments<\/td><\/tr><tr><td><strong>Leading Institution<\/strong><\/td><td>Henan Cancer Hospital (Medical Ethics Committee approved)<\/td><\/tr><tr><td><strong>First Enrollment<\/strong><\/td><td>14\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Full patient enrollment targeted for Q3\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Class\u202f1 innovative chemical drug (novel molecular entity)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Under evaluation; preclinical data suggest <strong>central\/peripheral analgesic pathway<\/strong> modulation distinct from opioids<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First oncology supportive care asset in Pien Tze Huang\u2019s pipeline; addresses <strong>unmet need<\/strong> for non\u2011opioid cancer pain therapies in China<\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> Current options limited to <strong>opioids<\/strong> and <strong>NSAIDs<\/strong>, carrying addiction and GI bleeding risks; PZH2108 aims to provide <strong>improved safety profile<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Cancer Pain Patients<\/strong><\/td><td>~<strong>2.8\u202fmillion<\/strong> (2024)<\/td><\/tr><tr><td><strong>Current Treatment Paradigm<\/strong><\/td><td>Opioids (70% share), NSAIDs (25%), adjuvants (5%)<\/td><\/tr><tr><td><strong>Cancer Pain Market Size<\/strong><\/td><td>\u00a512\u202fbillion (US$1.6\u202fbillion)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>8% (2024\u20112030)<\/td><\/tr><tr><td><strong>Revenue Forecast (PZH2108)<\/strong><\/td><td><strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (US$110\u2011160\u202fmillion) peak sales by 2032<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>8\u201112% of moderate\u2011to\u2011severe cancer pain segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong> No novel non\u2011opioid cancer pain drugs approved in China since 2018; <strong>AstraZeneca\u2019s naloxegol<\/strong> and <strong>Pfizer\u2019s tapentadol<\/strong> address opioid\u2011induced side effects but not underlying pain mechanism<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> Phase\u202fIIa safety data expected <strong>Q1\u202f2027<\/strong>; Phase\u202fIIb dosing study initiation <strong>H2\u202f2027<\/strong> if safety profile is favorable<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> BTD eligibility likely if Phase\u202fIIb demonstrates <strong>superior efficacy vs. standard of care<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding PZH2108\u2019s clinical development, regulatory pathway, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics in the cancer pain market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600436_20251121_KGQU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600436_20251121_KGQU.\"><\/object><a id=\"wp-block-file--media-7268120c-d362-4b79-9c26-98f57d32d3a7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600436_20251121_KGQU.pdf\">600436_20251121_KGQU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600436_20251121_KGQU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7268120c-d362-4b79-9c26-98f57d32d3a7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48786,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,640,1327],"class_list":["post-48783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-pien-tze-huang-pharmaceutical","tag-sha-600436"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pien Tze Huang&#039;s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first patient in a Phase\u202fIIa clinical trial for PZH2108 tablets, a Class\u202f1 innovative chemical drug intended for the treatment of cancer pain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48783\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pien Tze Huang&#039;s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient\" \/>\n<meta property=\"og:description\" content=\"Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first patient in a Phase\u202fIIa clinical trial for PZH2108 tablets, a Class\u202f1 innovative chemical drug intended for the treatment of cancer pain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48783\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-22T14:20:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-22T14:20:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pien Tze Huang&#8217;s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient\",\"datePublished\":\"2025-11-22T14:20:20+00:00\",\"dateModified\":\"2025-11-22T14:20:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2201.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Pien Tze Huang Pharmaceutical\",\"SHA: 600436\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48783#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48783\",\"name\":\"Pien Tze Huang's PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2201.webp\",\"datePublished\":\"2025-11-22T14:20:20+00:00\",\"dateModified\":\"2025-11-22T14:20:21+00:00\",\"description\":\"Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first patient in a Phase\u202fIIa clinical trial for PZH2108 tablets, a Class\u202f1 innovative chemical drug intended for the treatment of cancer pain.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48783\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pien Tze Huang's PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48783#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pien Tze Huang&#8217;s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pien Tze Huang's PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient - Insight, China&#039;s Pharmaceutical Industry","description":"Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first patient in a Phase\u202fIIa clinical trial for PZH2108 tablets, a Class\u202f1 innovative chemical drug intended for the treatment of cancer pain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48783","og_locale":"en_US","og_type":"article","og_title":"Pien Tze Huang's PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient","og_description":"Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first patient in a Phase\u202fIIa clinical trial for PZH2108 tablets, a Class\u202f1 innovative chemical drug intended for the treatment of cancer pain.","og_url":"https:\/\/flcube.com\/?p=48783","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-22T14:20:20+00:00","article_modified_time":"2025-11-22T14:20:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48783#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48783"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pien Tze Huang&#8217;s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient","datePublished":"2025-11-22T14:20:20+00:00","dateModified":"2025-11-22T14:20:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48783"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48783#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2201.webp","keywords":["Clinical trial approval \/ initiation","Pien Tze Huang Pharmaceutical","SHA: 600436"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48783#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48783","url":"https:\/\/flcube.com\/?p=48783","name":"Pien Tze Huang's PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48783#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48783#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2201.webp","datePublished":"2025-11-22T14:20:20+00:00","dateModified":"2025-11-22T14:20:21+00:00","description":"Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first patient in a Phase\u202fIIa clinical trial for PZH2108 tablets, a Class\u202f1 innovative chemical drug intended for the treatment of cancer pain.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48783#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48783"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48783#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2201.webp","width":1080,"height":608,"caption":"Pien Tze Huang's PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48783#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pien Tze Huang&#8217;s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48783"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48783\/revisions"}],"predecessor-version":[{"id":48787,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48783\/revisions\/48787"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48786"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}